In partnership with

Become the go-to AI expert in 30 days

AI keeps coming up at work, but you still don't get it?

That's exactly why 1M+ professionals working at Google, Meta, and OpenAI read Superhuman AI daily.

Here's what you get:

• Daily AI news that matters for your career - Filtered from 1000s of sources so you know what affects your industry.

• Step-by-step tutorials you can use immediately - Real prompts and workflows that solve actual business problems.

• New AI tools tested and reviewed - We try everything to deliver tools that drive real results.

• All in just 3 minutes a day

Join 1M+ pros

Introduction

Caffeine is the most widely consumed psychoactive compound in the world. Yet despite decades of speculation, its long-term relationship with cognitive decline has remained unclear. A newly published large-scale prospective study in JAMA tracked more than 131,000 adults over four decades to examine whether habitual intake of caffeinated coffee, tea, and total caffeine relates to dementia risk and cognitive performance. The scale, duration, and methodological rigor of this dataset make it one of the most comprehensive analyses to date.

The research drew from two of the most established U.S. longitudinal cohorts: the Nurses’ Health Study and the Health Professionals Follow-up Study. Participants were free of dementia at baseline and provided repeated dietary data using validated food frequency questionnaires. Instead of relying on a single snapshot of intake, researchers calculated cumulative average consumption across decades—capturing long-term habitual exposure rather than short-term behavior.

Dementia cases were identified through physician diagnoses and death records, with additional validation through biomarkers such as APOE4 genotype and plasma p-tau217 in sub-analyses. Statistical models adjusted for education, physical activity, smoking, alcohol intake, cardiometabolic disease, diet quality, and socioeconomic factors. Importantly, exposures and covariates were treated as time-varying, strengthening inference and reducing bias.

This level of adjustment matters. It helps isolate caffeine’s association from lifestyle confounders—an essential step in interpreting observational data.

What the Data Showed

Across 4.3 million person-years of follow-up, higher intake of caffeinated coffee and tea was associated with lower dementia incidence. Participants in the highest quartile of caffeinated coffee intake had approximately an 18% lower risk of dementia compared to those in the lowest quartile after full adjustment. Tea intake showed a similar inverse pattern.

The dose-response analysis revealed a nonlinear curve. The lowest dementia risk clustered around roughly 2–3 cups of coffee per day (approximately 300 mg of caffeine). Higher intake did not produce additional benefit. The association was specific to caffeinated beverages—decaffeinated coffee did not demonstrate a similar protective relationship.

Objective cognitive testing in older participants showed modest but measurable differences. Higher caffeine intake was associated with slightly better scores on standardized telephone-based cognitive tests. The magnitude was small at the individual level, roughly equivalent to less than a year of cognitive aging, but meaningful at a population scale.

Importantly, these patterns were consistent across multiple sensitivity analyses and were not dependent on genetic risk for Alzheimer’s disease.

Mechanisms & Neuroscience

Adenosine Signaling and Neural Excitability

Caffeine’s primary mechanism is antagonism of adenosine receptors, particularly A1 and A2A receptors. Adenosine normally acts as a neuromodulator that dampens neuronal firing and promotes sleep pressure. By blocking these receptors, caffeine increases cortical excitability and modulates dopaminergic signaling.

Chronic adenosine receptor modulation may influence neurodegenerative processes. A2A receptors are expressed in regions vulnerable to Alzheimer’s pathology, including the hippocampus and basal ganglia. Experimental models suggest that long-term caffeine exposure can alter synaptic plasticity and reduce maladaptive signaling cascades linked to cognitive decline.

This receptor-level interaction provides biological plausibility for why caffeinated, but not decaffeinated, beverages showed associations with cognitive outcomes.

Amyloid, Tau, and Alzheimer’s Pathophysiology

Alzheimer’s disease is characterized by accumulation of amyloid-beta plaques and hyperphosphorylated tau tangles. Experimental research has shown that caffeine exposure may influence both amyloid production and tau-related pathways, potentially reducing pathological aggregation.

Additionally, caffeine has been implicated in enhancing autophagic and lysosomal pathways, cellular systems responsible for clearing misfolded proteins. While the cohort study did not directly measure plaque burden, the epidemiological findings align with these mechanistic pathways described in experimental literature.

This convergence between long-term human data and laboratory models strengthens the plausibility of a neuroprotective association.

Neuroinflammation and Vascular Integrity

Neurodegeneration rarely occurs in isolation from vascular and inflammatory processes. Chronic neuroinflammation, microglial activation, endothelial dysfunction, and impaired cerebral blood flow all contribute to cognitive decline.

Caffeine has been associated in prior research with reduced inflammatory signaling and improved vascular function. It also influences insulin sensitivity and metabolic regulation, factors tightly linked to brain aging and vascular dementia risk.

Given that dementia is increasingly understood as a multifactorial process involving metabolic, vascular, and inflammatory components, caffeine’s broad systemic effects may partially explain the observed associations.

Why the Effect Plateaued: Physiological Saturation

The nonlinear pattern observed in the data is biologically meaningful. Caffeine is metabolized primarily through the CYP1A2 enzyme system. At higher doses, enzymatic activity can reach functional saturation, limiting incremental physiological impact.

Beyond metabolic limits, excessive caffeine intake may impair sleep architecture or increase anxiety—both of which negatively influence cognitive health. This dual dynamic likely explains why benefits clustered around moderate intake rather than increasing indefinitely.

The brain appears responsive to caffeine within a certain physiological range, not in proportion to ever-increasing dosage.

Practical Applications for Brain Health

The findings do not suggest caffeine is a cure for dementia. They indicate that moderate intake, approximately 2–3 cups of coffee per day, aligns with more favorable cognitive aging trajectories at the population level.

Individual variability matters. Genetic differences in caffeine metabolism, sleep sensitivity, and cardiovascular health influence how caffeine affects each person. Timing also matters—morning intake may minimize sleep disruption while preserving potential benefits.

Caffeine should be viewed as one component within a broader brain-health framework that includes sleep, exercise, metabolic health, and vascular protection. Its role appears supportive, not singular.

The Bottom Line

Across four decades of follow-up, moderate caffeine intake was consistently associated with lower dementia incidence and modestly better cognitive performance. The pattern suggests caffeine interacts with core neurodegenerative, vascular, and inflammatory pathways in a dose-sensitive manner rather than producing a simple linear effect.

Morning coffee is not a magic shield, but within a physiological range, it appears to align with healthier brain aging trajectories.

Reference

Coffee and Tea Intake, Dementia Risk, and Cognitive Function
JAMA (2026)
DOI: 10.1001/jama.2025.27259